--- title: "Interventional Myeloma EQUATE EAA181 | Sutter Health" description: "Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation" url: "https://www.sutterhealth.org/research/clinical-trials/interventional-myeloma-equate-eaa181-1049141964" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Interventional Myeloma EQUATE EAA181 # Interventional Myeloma EQUATE EAA181 **Status:** Open to Enrollment [Email us to enroll](https://www.sutterhealth.org/research/clinical-trials/interventional-myeloma-equate-eaa181-1049141964#enroll) #### Study details View study details on [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04566328). #### Locations - Sutter Health System Wide #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial. This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone. ![Ari D Baron, M.D.](https://dyn.mktgcdn.com/p/6yRtgxCIIRXiFOeBSBsWHHTovMS-k88mwc-hVtYQXNU/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Ari D Baron, M.D. Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/ari-d-baron-md-1049681174) ## Email us to enroll - [Email Sutter Health System Wide](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Interventional%20Myeloma%20EQUATE%20EAA181%20in%20Sutter%20Health%20System%20Wide&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Multiple Myeloma Expanded Access to Ciltacabtagene Autoleucel (Cilta-Cel) 68284528MMY4006](https://www.sutterhealth.org/research/clinical-trials/multiple-myeloma-expanded-access-to-ciltacabtagene-autoleucel-cilta-cel-68284528mmy4006-2048816446) Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma **Status:** Open to Enrollment - Clinical trial ### [Multiple Myeloma Expanded Access to Idecabtagene Vicleucel BB2121-EAP-001](https://www.sutterhealth.org/research/clinical-trials/multiple-myeloma-expanded-access-to-idecabtagene-vicleucel-bb2121-eap-001-2062975937) Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release **Status:** Coming Soon - Clinical trial ### [Adjuvant Large B-Cell Lymphoma Alpha3](https://www.sutterhealth.org/research/clinical-trials/adjuvant-large-b-cell-lymphoma-alpha3-1095534994) A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma **Status:** Open to Enrollment - Clinical trial ### [Cancer Young Female Adults Ovarian Damage Prevention ALTE2131](https://www.sutterhealth.org/research/clinical-trials/cancer-young-female-adults-ovarian-damage-prevention-alte2131-2027477841) Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults With Cancer **Status:** Open to Enrollment - Clinical trial ### [Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma J2N-MC-JZNX](https://www.sutterhealth.org/research/clinical-trials/chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-j2n-mc-jznx-1095539412) A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With a Covalent Bruton Tyrosine Kinase Inhibitor **Status:** Open to Enrollment [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/interventional-myeloma-equate-eaa181-1049141964#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Interventional Myeloma EQUATE EAA181"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/interventional-myeloma-equate-eaa181-1049141964#medicalwebpage","name":"Interventional Myeloma EQUATE EAA181","description":"Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation","url":"https://www.sutterhealth.org/research/clinical-trials/interventional-myeloma-equate-eaa181-1049141964","inLanguage":"en-US","dateModified":"2026-05-21","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/interventional-myeloma-equate-eaa181-1049141964#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/interventional-myeloma-equate-eaa181-1049141964#breadcrumblist"},"mentions":[{"@type":"Person","name":"Ari D Baron, M.D.","url":"https://www.sutterhealth.org/research/investigators/ari-d-baron-md-1049681174","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/interventional-myeloma-equate-eaa181-1049141964#medicaltrial","name":"Interventional Myeloma EQUATE EAA181","alternateName":"Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation","url":"https://www.sutterhealth.org/research/clinical-trials/interventional-myeloma-equate-eaa181-1049141964","description":"Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial. This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.","identifier":"NCT04566328","code":{"@type":"MedicalCode","codeValue":"NCT04566328","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://clinicaltrials.gov/study/NCT04566328","status":"https://schema.org/Recruiting","healthCondition":[{"@type":"MedicalCondition","name":"Hematologic Cancer"}],"studyLocation":[{"@type":"AdministrativeArea","name":"Sutter Health System Wide"}]} ```